Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 281
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
Mindset Pharma Announces $5 Million Bought Deal Financing
MindMed Announces Inclusion in FTSE Russell Indexes
Psychedelic Bulletin: Australian Gov Earmarks $15m for Psychedelic Studies; Otsuka Licences...
Numinus Announces Closing of $40-Million Bought Deal Financing
Red Light Holland Closes Acquisition of SR Wholesale Becoming a Leader...
PTSF51 – Miracle Cures, Money, and Standing on the Shoulders of...
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect...
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic...
Novamind Partners with Merck for New Treatment-Resistant Depression Trial
Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics
Load more